Wipfli Financial Advisors LLC Makes New $29,000 Investment in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Wipfli Financial Advisors LLC purchased a new position in Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 681 shares of the life sciences company’s stock, valued at approximately $29,000.

Other hedge funds have also recently added to or reduced their stakes in the company. California Public Employees Retirement System grew its position in Integra LifeSciences by 1.1% in the second quarter. California Public Employees Retirement System now owns 157,344 shares of the life sciences company’s stock worth $8,501,000 after buying an additional 1,688 shares during the last quarter. Trexquant Investment LP boosted its stake in Integra LifeSciences by 46.7% in the 2nd quarter. Trexquant Investment LP now owns 19,077 shares of the life sciences company’s stock worth $1,031,000 after purchasing an additional 6,075 shares during the period. Nisa Investment Advisors LLC boosted its stake in Integra LifeSciences by 15.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 28,400 shares of the life sciences company’s stock worth $1,534,000 after purchasing an additional 3,800 shares during the period. WINTON GROUP Ltd acquired a new position in Integra LifeSciences in the 2nd quarter worth approximately $255,000. Finally, Tandem Capital Management Corp ADV boosted its stake in Integra LifeSciences by 3.6% in the 2nd quarter. Tandem Capital Management Corp ADV now owns 22,763 shares of the life sciences company’s stock worth $1,230,000 after purchasing an additional 785 shares during the period. Institutional investors and hedge funds own 87.60% of the company’s stock.

Integra LifeSciences Stock Up 0.9 %

IART stock opened at $55.28 on Friday. The company has a current ratio of 3.93, a quick ratio of 2.91 and a debt-to-equity ratio of 0.86. Integra LifeSciences Holdings Co. has a 1 year low of $40.67 and a 1 year high of $69.61. The company has a fifty day simple moving average of $55.62 and a 200 day simple moving average of $51.67. The firm has a market cap of $4.62 billion, a PE ratio of 26.84, a PEG ratio of 1.61 and a beta of 1.14.

Integra LifeSciences (NASDAQ:IARTGet Rating) last released its quarterly earnings data on Wednesday, October 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.14. Integra LifeSciences had a net margin of 11.05% and a return on equity of 16.41%. The business had revenue of $385.19 million during the quarter, compared to analyst estimates of $377.79 million. Sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 3.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on IART. JMP Securities decreased their price objective on shares of Integra LifeSciences from $85.00 to $75.00 and set a “market outperform” rating for the company in a research note on Thursday, October 27th. Jefferies Financial Group assumed coverage on shares of Integra LifeSciences in a research note on Tuesday, October 11th. They issued a “hold” rating and a $48.00 price objective for the company. Citigroup lifted their target price on shares of Integra LifeSciences from $50.00 to $60.00 and gave the company a “neutral” rating in a research note on Monday, December 12th. Truist Financial lifted their target price on shares of Integra LifeSciences from $52.00 to $58.00 and gave the company a “hold” rating in a research note on Tuesday, December 20th. Finally, Morgan Stanley lifted their target price on shares of Integra LifeSciences from $50.00 to $59.00 and gave the company an “equal weight” rating in a research note on Friday, January 6th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $58.33.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

See Also

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.